Skip to search formSkip to main contentSkip to account menu

lexatumumab

A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2… 
National Institutes of Health

Related topics

Related topics

8 relations
IMC 1121BInhibition of Cell ProliferationPositive Regulation of ApoptosisTNFRSF10B protein, human
Expand

Narrower (1)

LY3009806

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.
PURPOSE Lexatumumab is an agonistic, fully human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing… 
2012
2012
RIP1 Protein-dependent Assembly of a Cytosolic Cell Death Complex Is Required for Inhibitor of Apoptosis (IAP) Inhibitor-mediated Sensitization to Lexatumumab-induced Apoptosis*
Background: Rhabdomyosarcomas (RMS) are often resistant to TRAIL-induced apoptosis. Results: IAP inhibitors prime RMS cells to… 
Highly Cited
2010
Highly Cited
2010
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.
BACKGROUND Lexatumumab (HGS-ETR2) is a fully human agonistic mAb to the tumor necrosis factor-related apoptosis-inducing ligand… 
Highly Cited
2010
Highly Cited
2010
TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5
Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) and agonistic anti-DR4/TRAIL-R1 and anti-DR5/TRAIL-R2 antibodies… 
Highly Cited
2009
Highly Cited
2009
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
Mapatumumab and lexatumumab are fully human monoclonal antibodies that bind and activate human tumor necrosis factor-related… 
Highly Cited
2007
Highly Cited
2007
Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
Purpose: To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of… 
Highly Cited
2007
Highly Cited
2007
Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin
BackgroundThe incidence of malignant pleural mesothelioma (MPM) is associated with exposure to asbestos, and projections suggest… 
2007
2007
A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.
Highly Cited
2007
Highly Cited
2007
Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) preferentially induces apoptosis in malignant cells by binding to… 
Highly Cited
2007
Highly Cited
2007
A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI
14006 Background: Lexatumumab (HGS-ETR2) is a fully-human agonistic monoclonal antibody that targets and activates the Tumor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License